Skip to content

Debt-to-assets at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
0.3×0.0×
Merck & Co. logo
Merck & Co.MRK
0.4×+0.1×
CG Oncology logo
CG OncologyCGON
0.0×
Arvinas logo
ArvinasARVN
0.0×
Replimune Group logo
Replimune GroupREPL
0.2×+0.1×
Immunome logo
ImmunomeIMNM
0.0×

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Calculated from Relmada Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed August 7, 2024, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s debt-to-assets?
Relmada Therapeutics, Inc. (RLMD) reported debt-to-assets of 0.9× in Q2 2023.
How has Relmada Therapeutics, Inc.'s debt-to-assets changed year-over-year?
Relmada Therapeutics, Inc.'s debt-to-assets increased by 5.3% year-over-year, from 0.8× to 0.9×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.